Canipil

Quick links to important sections

Canipil

Method of action: Endocrine Therapy

Treatment option: Anorexia, Cachexia, Cancer, Breast Cancer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canipil

Quick Facts

  • Active Ingredient: Megestrol (as megestrol acetate)
  • Drug Class: Synthetic progestin (progesterone-like hormone)
  • Primary Use (Veterinary): Temporary control of the estrous cycle (heat) and certain behavioral/skin conditions in female dogs and cats.

Canipil is a veterinary prescription medication whose active ingredient is megestrol acetate, a synthetic version of the naturally occurring female sex hormone, progesterone. As a powerful progestin, it exerts anti-estrogenic effects within the body. In veterinary medicine, megestrol acetate is primarily used for its hormonal properties to manage reproductive cycles in female dogs and cats.

Specifically, its approved uses include the postponement or temporary prevention of the estrous (heat) cycle in female dogs and cats. In male dogs, it has also been indicated for the treatment of certain manifestations of hypersexuality or undesirable behavior. Additionally, it may be used in cats for the treatment of specific skin conditions, such as miliary eczema and eosinophilic granulomata.

It is important to note that megestrol acetate is a potent hormone that must be used strictly under veterinary guidance. Due to the potential for side effects, its use is typically limited to short-term applications or when surgical sterilization is not immediately feasible.

What side effects are possible with Canipil?

Canipil: Possible Side Effects and Safety Information

Canipil (canagliflozin) may be associated with various adverse reactions, including potentially serious events, as outlined in regulatory documentation. The safety profile requires specific monitoring and attention to pre-existing conditions.

Common Adverse Reactions

Adverse reactions reported with an incidence of 5% or greater include female genital mycotic infections, urinary tract infection (UTI), and increased urination. The mechanism of action, which involves increasing the excretion of glucose in the urine, is related to the higher incidence of genital mycotic infections and UTIs.

Serious and Clinically Significant Risks

  • Lower Limb Amputation: An increased risk of lower limb amputations (primarily toes and feet) has been observed in clinical trials, requiring careful monitoring for new pain, tenderness, sores, ulcers, or infections in the legs and feet. This risk remains a warning in the Prescribing Information.
  • Ketoacidosis: Cases of diabetic ketoacidosis (DKA) have been reported, sometimes presenting with blood glucose levels below 250 mg/dL. This is a life-threatening emergency.
  • Acute Kidney Injury and Renal Impairment: The medication can cause intravascular volume contraction, which may lead to symptomatic hypotension and acute kidney injury, particularly in patients with pre-existing renal impairment or those on diuretics. Frequent monitoring of renal function is advised.
  • Other Serious Risks: These include Fournier's gangrene (a rare, serious necrotizing fasciitis of the perineum), urosepsis and pyelonephritis (severe UTIs), and hypersensitivity reactions.

Population-Specific and Dose-Related Considerations

Canipil is contraindicated in patients with a history of serious hypersensitivity reactions or severe renal impairment (eGFR less than 30 mL/min/1.73 m^2). Geriatric patients and those with existing renal impairment have a higher documented incidence of adverse reactions related to reduced intravascular volume. Dose-related patterns, such as the increased risk of lower limb amputation, were observed across both the 100 mg and 300 mg once-daily dosage regimens. Temporary interruption of therapy may be required in situations that predispose to acute volume loss, such as gastrointestinal illness or prior to major surgery.

Overdose and Emergency Response

Overdose and when to seek help

Overexposure to Canipil (megestrol acetate) requires immediate medical attention. Regulatory documents describe the management of overdose as relying solely on appropriate supportive measures, since no specific antidote is known. The official labeling indicates that dialysis is not expected to be an effective means of treatment due to the drug's low solubility.

The documented clinical manifestations reported in post-marketing cases following overdosage include gastrointestinal effects such as diarrhoea, nausea, and abdominal pain. Systemic and other signs observed include chest pain, shortness of breath, cough, unsteady gait, and listlessness. The presence of symptoms such as chest pain and shortness of breath are considered significant clinical manifestations that necessitate urgent medical evaluation and intervention.

The overdose profile also carries specific population considerations. The risk of toxic reactions may be greater in individuals with impaired renal function due to the drug's substantial excretion via the kidney. Caution is also advised for elderly patients, who are more likely to have decreased renal function, thereby potentially increasing the risk of toxicity. The official profile mandates symptom management and heightened awareness for these at-risk groups.

Therapeutic Uses of Canipil

Temporary Management of Reproductive Cycles and Symptoms

Canipil (megestrol acetate) is applied in addressing certain symptoms related to systemic imbalance and reproductive issues in female animals. This medication is used for the temporary postponement of the estrous (heat) cycle in dogs. It is also relevant for managing symptoms that cluster into patterns requiring supportive management, such as those associated with false pregnancy (pseudopregnancy) in dogs, and provides support that helps ease the overall symptom burden during these episodes.


Control of Hormone-Driven Undesirable Behaviors and Specific Skin Issues

This medication is considered relevant in contexts marked by increased discomfort or tension due to hormone-driven issues, such as hypersexuality in male dogs. It assists with managing symptoms that interfere with daily comfort, such as excessive urine marking or aggression in cats. Furthermore, it is applied across domains where additional symptomatic support is needed for inflammatory skin conditions in cats, including miliary eczema and the eosinophilic granuloma complex.


Quick Fact: Conditions Supported
Applied in conditions involving: temporary postponement of estrus, supportive relief for false pregnancy symptoms, management of hypersexuality, and symptomatic support for specific feline inflammatory skin issues.

Eligibility and Restrictions for Use

Who Can and Cannot Use Canipil? — Official Regulatory Information

Eligibility for Canipil (megestrol acetate) is strictly defined by regulatory authorities and is based on the animal's reproductive status, existing health conditions, and intended purpose.


Official Eligibility Restrictions

Classification Population Restriction (Official Status)
Absolute Contraindications Animals with known hypersensitivity to the drug, uterine disease, uterine bleeding, or mammary tumors must not be treated.
Not Recommended/Restricted Pregnant animals and diabetic animals are generally not recommended for treatment. Male dogs intended for breeding should not be treated.
Conditional Use (Caution) The medicine must be used with caution in animals with impaired liver function. Use in lactating pets requires caution as the substance enters the milk and effects on suckling offspring are unknown.

Age and Comorbidity Rules

Special precautions are required for bitches treated at their first estrus. This medicine is reserved for use in dogs and cats where no contraindications or major restrictions are present, ensuring strict compliance with officially documented population limits.

What should I know about interactions with other medicines?

The interaction profile for Canipil (megestrol acetate) is defined by pharmacokinetic and pharmacodynamic relationships documented in regulatory prescribing information.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Category Official Regulatory Description
Antiretroviral Agents Co-administration may cause a significant decrease in the plasma exposure of certain protease inhibitors, such as Indinavir.
Anticoagulants The drug may interact with Warfarin and cause an increase in the International Normalized Ratio (INR), requiring close monitoring of coagulation parameters.
Anti-diabetic Agents A pharmacodynamic interaction may lead to impaired glucose tolerance or exacerbation of pre-existing diabetes, potentially resulting in increased insulin requirements.

Interaction-Related Statements

Regulatory documents include specific statements regarding the lack of interaction with certain compounds, noting that no significant alterations in the pharmacokinetic parameters of Zidovudine or Rifabutin were observed when co-administered. The official prescribing information also notes that no known interactions with food are documented.

Population-Specific Caution

An interaction caution exists for elderly patients and those with impaired renal function because the drug is substantially excreted by the kidney. This may lead to an increased risk of toxic reactions due to reduced clearance in these populations.

The overall profile requires clinical assessment of concomitant medications, particularly those that affect metabolism or glucose regulation, in accordance with the official regulatory labeling.

Mechanism of Action

How Canipil Works

Targeting Hormonal Receptors

Canipil works by directly binding to and activating progesterone receptors ( PR) inside cells, acting as a PR agonist. This interaction alters genetic transcription and initiates the primary cascade of effects via sustained progestational signaling.

Modulating the HPO Axis

The drug's action includes providing negative feedback to the central Hypothalamic-Pituitary-Ovarian ( HPO) axis. This central control mechanism is suppressed, resulting in significantly decreased release of the key reproductive hormones, luteinizing hormone ( LH) and follicle-stimulating hormone ( FSH), which restricts the signals driving the reproductive cycle.

Altering Tissue and Cellular State

A direct consequence of the hormonal signaling is a shift in the physiological state of reproductive tissues. This includes inhibiting the process of ovulation and causing the endometrium to become less structurally receptive, leading to specific physiological adjustments in the reproductive tract.

Dosage and Administration Information

Canipil (megestrol acetate) is administered via the oral route, following standardized dosage protocols. The tablets may be given either intact or crushed and mixed with food to facilitate consumption. This intake method is the administration procedure detailed in the prescribing information.


Dosing and Scheduling Regimens

Dosing frequency and dosage amounts are linked to the species and the intended usage pattern. For dogs, the regimen is typically calculated based on body weight, with daily doses ranging from 0.25 to 1 mg per pound of body weight, depending on the stage of the estrous cycle.

In cats, schedules often rely on fixed-dose amounts. Short-term use, such as suppression courses, requires a 5 mg dose administered daily for a short, defined period. For long-term use, a lower dose of 2.5 mg may be scheduled weekly or fortnightly.

Administration Requirement Specification
Duration Constraint Canine use is restricted to not more than twice in any 12-month period.
Course Commencement Estrus postponement must begin at least seven days before the desired effect is required, defining a specific preparatory timing.

These instructions define the standardized approach to using the medicine, focusing on the procedural steps for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Canipil (Megestrol Acetate)

This overview describes the types of research and general findings for the approved uses of megestrol acetate in animals, according to regulatory and scientific sources. The information focuses only on the structure of the evidence and does not provide clinical instructions or recommendations.


Evidence for Managing Reproductive Cycles (Estrus and Pseudopregnancy)

Research related to managing reproductive cycles in female animals has included both historical clinical trials and field experience reports. These studies were used in research exploring how symptoms change over time and which populations were included in the early use of the medication. For female dogs and cats, megestrol acetate was studied for the temporary control or postponement of the estrous cycle (heat or calling). Researchers tracked outcomes related to the rate of suppression and the time until the next heat cycle began.

For false pregnancy (pseudopregnancy) symptoms in dogs, research has explored whether it influences the associated clinical signs. Evidence is limited for this indication compared to newer treatment options, and studies are often historical. Data show patterns related to symptom remission during treatment, but there are reports suggesting symptoms may recur after the medication is discontinued.


Evidence for Behavioral Management in Male Dogs

Research examined the use of megestrol acetate in male dogs exhibiting undesirable behaviors linked to hypersexuality. Studies were typically smaller non-randomized trials or field reports where owners reported the severity and frequency of behaviors like inappropriate marking or mounting.

Studies report patterns observed related to behavioral outcomes during the short-term administration period. Research provides insight into short-term changes in these outcomes. Research relies heavily on patient-reported outcomes, which reflects a known study limitation in measuring behavior. Follow-up durations were limited in many studies, and there is limited information for long-term outcomes regarding the duration of the reported changes after treatment ends.


Study Limitations and Research Gaps (What is Still Uncertain)

The evidence landscape contributes to understanding symptom patterns, but significant limitations exist. Evidence quality varies across studies, with many foundational data points relying on historical clinical experience and smaller, non-randomized trials. Comparative evidence is lacking in several areas, meaning there are few head-to-head studies comparing megestrol acetate against current alternative therapies. For all indications, data for certain groups remain insufficient, and the results apply only to the populations studied, meaning the research does not determine whether an individual animal will respond similarly.

Key Studies & References

  1. Summary of Product Characteristics (SPC) Ovarid 5mg Tablets - HPRA (Irish regulatory document used for indications)
  2. Estrous cycle manipulation in dogs - Clinical Theriogenology (2012 review article for context)

Frequently Asked Questions (FAQ)

Common questions about Canipil (FAQ)

Q: Is Canipil available over the counter?

A: No, according to regulatory documents, the medication is categorized as a prescription-only drug. It requires a legal prescription from a healthcare provider to obtain.

Q: Can older adults safely use Canipil?

A: Official product information indicates that insufficient data exists from clinical studies specifically for patients 65 years of age and older to determine if they respond differently than younger adults. However, other clinical experience has not identified differences in the way older patients respond. Since this group may have existing conditions like impaired kidney function, this highlights the importance of a professional consultation before starting the medication.

Q: Is there any research evidence showing Canipil works for its intended purpose?

A: Studies and clinical data reviewed by regulatory authorities form the basis for the drug's approved uses. This medication is officially indicated for its purpose, such as the palliative treatment of advanced breast or endometrial cancer, and the management of unexplained weight loss or cachexia in AIDS patients.

Q: How long can a person safely use Canipil?

A: Regulatory information does not set a universal maximum duration for use. However, the chronic administration of the drug is associated with increased risks of specific adverse effects. These risks include the potential for adrenal insufficiency and the new onset or worsening of diabetes mellitus.

Q: What are the possible long-term effects of Canipil use?

A: According to official warnings, long-term or chronic use is associated with a risk of developing specific conditions. These include adrenal insufficiency, which is related to suppressed adrenal gland function. The development of new or worsened diabetes mellitus and a condition known as Cushing's syndrome are also noted as possible long-term effects.

Q: Why do official documents refer to Canipil as a 'non-selective modulator'?

A: Official regulatory documents primarily classify the active substance as a progestin. A progestin is a synthetic progestational drug and an agonist of the progesterone receptor.

Q: Does Canipil require any special monitoring while in use?

A: Yes, regulatory documentation indicates that special monitoring may be necessary, particularly with chronic use. This includes monitoring for signs of adrenal insufficiency, which affects the body's ability to produce necessary hormones. Monitoring for new onset or worsening diabetes mellitus, including checking blood glucose levels, may also be required.

Q: What are the signs of a serious allergic reaction to Canipil?

A: A serious allergic reaction, also known as a hypersensitivity reaction, is listed as a contraindication in the official information. The signs of such a reaction may include swelling of the face, lips, or tongue. Other serious signs include the presence of a severe skin rash or difficulty breathing.

Q: Is Canipil a new or an established medication?

A: The active substance in the drug is megestrol acetate, which is considered an established medication. The drug has been approved for various medical uses since the 1960s and 1970s, making it a well-documented synthetic progestational drug.

Q: What happens when you stop taking Canipil?

A: Official safety information indicates that stopping chronic therapy is associated with certain risks, including the potential development of signs suggestive of adrenal insufficiency. Light vaginal bleeding or spotting may also occur upon discontinuation of the medication.

Q: Is Canipil only for short-term use?

A: The specific duration of use is not universally fixed and should be determined on a case-by-case basis by a healthcare provider. However, official warnings regarding the long-term administration of the medication highlight specific risks, such as the potential for adrenal suppression.

Q: What happens if I forget to take a dose of Canipil?

A: Patient information advises against taking a double dose to make up for a missed dose. The general guidance is to resume the regular schedule as advised.

Q: Is it normal to feel tired when starting Canipil?

A: Yes, official safety information lists tiredness, or asthenia, and general feelings of weakness as common side effects associated with the medication.

Q: Does Canipil affect mood or sleep?

A: Yes, the official adverse reaction profile notes that the medication may affect both mood and sleep. Possible side effects include changes in mood, confusion, depression, and difficulty falling asleep or trouble sleeping.

Q: Can Canipil cause weight gain or loss?

A: According to the adverse reaction data, the medication is very commonly associated with an increase in appetite. This can lead to subsequent weight gain.

Q: Does Canipil interact with common pain relievers like ibuprofen?

A: Regulatory information notes potential drug interactions between the medication and certain pain relievers, including those categorized as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. These interactions could potentially alter the way either drug is processed in the body.

Q: Is Canipil a controlled substance?

A: Official regulatory classification indicates the drug is a prescription-only medication. It is not typically categorized as a scheduled controlled substance, such as those subject to specific narcotics control laws.

Q: Can Canipil affect the results of lab tests?

A: Yes, regulatory warnings indicate the drug may cause metabolic changes that could influence lab test results. For example, the medication can cause elevated blood glucose levels, which affects tests used to monitor blood sugar.

Q: Does Canipil have a risk of dependence or addiction?

A: Official prescribing information does not list any mention of a risk for dependence or addiction associated with the use of the drug.

Q: Is it necessary to take Canipil at the same time every day?

A: Patient information generally advises taking the medication at around the same time every day. Maintaining a consistent schedule helps to ensure the medication level in the body remains stable.

Q: What should I do if a minor side effect of Canipil does not go away?

A: Patient information states that side effects which continue over time or become troublesome warrant a consultation with a healthcare provider.

Q: Can Canipil affect fertility?

A: Official warnings advise women of childbearing potential to avoid becoming pregnant due to the potential for harm to the fetus. Possible side effects reported also include decreased sexual desire and erectile dysfunction.

Q: Does Canipil affect blood pressure?

A: Yes, according to the official adverse reaction profile, high blood pressure, known medically as hypertension, is listed as a very common side effect associated with this medication.

Q: Can Canipil be taken with antacids?

A: Potential drug interactions have been noted with certain antacid ingredients. These interactions could potentially alter the way the body processes the drug.

How should Canipil be stored and disposed of?

How to Store and Dispose of Canipil (Megestrol Acetate)

The storage and disposal requirements for this medication are strictly governed by regulatory labeling, focusing on product stability and safety.

Storage Conditions

The product must be stored at controlled room temperature, typically maintained below 25 C (77 F). To protect stability, the medication must be kept in its original container with the lid tightly closed to prevent moisture exposure. It should not be stored in environments prone to excessive heat or humidity.

Handling and Safety

Official labeling mandates that the product be stored out of the sight and reach of children. Due to its nature as a potent progestational agent, pregnant women should not handle the medication.

Disposal

Unused or expired megestrol acetate, including any waste materials, must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Canipil found in:

A-Z Index: